The Utility of PET/CT in gofitinib treatment for Non-small Cell Lung Cancer

The Utility of PET/CT in gofitinib treatment for Non-small Cell Lung Cancer - The Utility of PET/CT in gofitinib treatment for Non-small Cell Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003621

Enrollment

Registered

2010-05-17

Start date

2007-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

PET/CT 2days after gefitinib administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)NSCLC 2)Treatment with gefitinib 3)At least one measurable lesion 4)Age>20years 5)Perfomance status(PS)of 0 to 2 6)Written informed consent

Exclusion criteria

Exclusion criteria: 1)History of radiation therapy for primary site 2)Severe infection 3)Bowel obstruction 4)Interstital pneumonia or lung fibrosis 5)History of any thoracic radiation therapy 6)Active concmitant malignancy 7)Severe heart disease 8)No regulatory condition because of psychological disease 9)Pregnancy or women willing child-bearing 10)Inadequate condition diagosed by primary physician

Design outcomes

Primary

Measure	Time frame
Relationship between uptake of FDG 2days after gefitinib administration and tumor size on CT	—

Secondary

Measure	Time frame
PFS, OS, Rekationship between uptake of FDG 2days after gefitinib administration and EGFR mutation status	—

Countries

Japan

Contacts

Public ContactIsao Tachibana

Osaka University Graduate School of Medicine Department of Respiratory medicine, Allergy and Rheumatic Diseases

itachi02@imed3.med.osaka-u.ac.jp06-6879-3831

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026